{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-032925","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-07-13T11:05:37+00:00","discovered_at":"2026-07-13T11:10:05.658934+00:00","generated_at":"2026-07-13T11:10:11.220831+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tonix adds Medicare Part D coverage for TONMYA, expanding access to 145M lives by Jan 2027","bullets":["New Medicare agreement effective Jan 1, 2027 adds ~9M Medicare Part D lives (16% of U.S. Medicare).","Combined with prior commercial GPO deals and Medicaid, TONMYA coverage reaches ~145M lives (46% of U.S. covered lives).","Sales force to expand by 50 reps by mid-Q3 2026, total ~150 reps.","TONMYA is a first-in-class, non-opioid sublingual cyclobenzaprine for fibromyalgia.","Positive launch metrics cited: new prescribers, new patients, total and refill prescriptions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-032925","json":"https://secwatch.observer/filing/0001493152-26-032925.json","markdown":"https://secwatch.observer/filing/0001493152-26-032925.md","text":"https://secwatch.observer/filing/0001493152-26-032925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226032925/0001493152-26-032925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226032925/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T11:10:11.220831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}